BMS-986278

Refoxy Pharma secures $9.58 million to develop IPF drug RP-01 targeting FOXO3. Boehringer Ingelheim plans NDA submission for nerandomilast. Insilico's ISM001-055 and Endeavor's ENV-101 show disease improvement. Vicore's buloxibutid and BMS' BMS-986278 also chart progress. Pliant's bexotegrast mitigates chronic cough in IPF. IPOs and partnerships fuel IPF therapeutic field.

The Systemic Sclerosis Treatment Market is projected to grow significantly by 2034, driven by increasing prevalence, awareness, and FDA approvals like CABA-201's Orphan Drug and Fast Track Designations. Key players include Kyowa Hakko Kirin, AstraZeneca, and others, with therapies such as LUMICEF and SAPHNELO leading the pipeline. The market's expansion is also fueled by ongoing clinical trials and the development of new treatments targeting systemic sclerosis and related conditions.

DelveInsight's report forecasts an increase in Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) cases by 2034, highlighting the UK's highest prevalence. With 83% of 64,000 cases diagnosed in 2023, there's a call for better screening. Females are more affected, and severe cases account for 30%. Emerging therapies like Mycophenolate mofetil and Nintedanib are promising, with companies like Genentech and Boehringer Ingelheim leading the market.